Table 1. Published Studies Assessing Time to Recurrence of Anal and Vulvar HSIL After Treatment.
| Source | Cohort Size, No. | HIV-Positive Patients, No. | Treatment Modality | Patients With Recurrence After Treatment, % | Time to Recurrence, Median, mo |
|---|---|---|---|---|---|
| Anal HSIL | |||||
| Pineda et al,17 2008 | 246 | 182 | Surgical | 57 | 19 |
| Goldstone et al,20 2011 | 96 | 44 | Infrared coagulation ablation | 62 (HIV-negative) | 14 (HIV-negative) |
| 91 (HIV-positive) | 17 (HIV-positive) | ||||
| Richel et al,13 2013 | 388 | 388 | Topical and electrocautery treatment | 67 | 18 |
| Vulvar HSIL | |||||
| Modesitt et al,18 1998 | 73 | Unknown | Excisional or surgical ablation | 46 (If positive surgical margins), 17 (if negative surgical margins) | 15 (In positive surgical margins) |
| 41 (In negative surgical margins) | |||||
| Jones et al,7 2005 | 405 | 5 | Excisional or surgical ablation | 50 (If positive surgical margins), 15 (if negative surgical margins) | 60 |
| Wallbillich et al,19 2012 | 303 | Unknown | Excisional, topical, and surgical ablation | 28.7 | 25 |
| Fehr et al,15 2013 | 464 | Unknown | Excisional, topical, and surgical ablation | 30 | 12 |
| Madeleine et al,21 2016 | 65 | Unknown | Surgical ablation | 33.8 | 36 |
| Satmary et al,14 2018 | 784 | 2 | Excisional, topical, and surgical ablation | 26.3 | 16.9 |
Abbreviation: HSIL, high-grade squamous intraepithelial lesions.